$10bn Sandoz Business May Be Sold Or Spun As Novartis Weighs Options

Novartis Aims To Provide Update ‘Towards End Of 2022’

 
• By Dean Rudge

Novartis finally has confirmed plans to begin a strategic review for its Sandoz generics and biosimilars business, following years of conjecture and suggestions from the market. However, the originator stressed that it will take its time with a decision, while underlining that keeping Sandoz is among its choices.

Businessman covering his face using a white paper with drawn question mark, like a mask, for hiding his identity. Isolated gray wall background.
Will Novartis spin out or sell Sandoz? • Source: Shutterstock

Novartis has announced plans to commence a strategic review of its $10bn Sandoz generics and biosimilars business, including for a potential divestment, following dedicated moves towards greater autonomy for Sandoz and much speculation around its long-term future as a subsidiary of the Novartis group.

“The review will explore all options, ranging from retaining the business to separation, in order to determine how to best maximize value for our shareholders,” Novartis announced, as

More from Strategy

More from Business